Developing a non-hormonal on-demand fast dissolving vaginal insert with a window of protection lasting 12 hours that could prevent HIV, other sexually transmitted infections, and pregnancy.
Developing a 5–7 day microarray patch containing Nestorone designed for use immediately prior to sex or as an emergency contraceptive with minimal impact on breakthrough bleeding.
Innovating a low-cost highly-effective nonsurgical method of permanent contraception for women who have completed desired family size, with an appropriate delivery technology for low-resource settings.
Designing a second-generation contraceptive vaginal system that will achieve a similar one year of sustained release to the FDA approved product while substantially lowering the cost.
Assessing the acceptability of a single pill for prevention of HIV and unintended pregnancy and testing whether a single pill increases adherence to oral pre-exposure prophylaxis (PrEP) compared with a pill providing PrEP alone.
Conducting a multi-site, open-label randomized clinical trial testing a 90-day contraceptive vaginal ring delivering Nestorone and estradiol, evaluating efficacy and bleeding control in continuous use and 2, 3, and 4-day ring-out regimens.
Supporting the development of a six-month contraceptive microarray patch by reviewing the applicator device, user studies, regulatory pathway, and preclinical activities.
Developing a 90-day vaginal ring that could prevent HIV infection, other sexually transmitted infections and pregnancy, and conducting behavioral studies to understand user-focused factors and promote adoption and use of this technology.
Evaluating safety and acceptability of a non surgical male circumcision device and providing evidence to inform prequalification by the World Health Organization and approval by the Food and Drug Administration.
Establishing potential biomarkers for use in household surveys as an easy and cost-effective approach for verifying assessments of contraceptive use and ultimately tracking progress toward increasing access to sexual and reproductive health services.